Risk of Fracture and the Concomitant Use of Bisphosphonates With Osteoporosis-Inducing Medications

Objective: To review the literature on the concomitant use of bisphosphonates and medications that can influence bone metabolism and potentially attenuate bisphosphonate antifracture efficacy. Data Sources: MEDLINE and CINAHL were searched for articles published in English through December 2014 using the following terms: bisphosphonates, bone density conservation agents, acid-suppressive therapy, levothyroxine, thiazolidinediones (TZDs), selective serotonin reuptake inhibitors (SSRIs), bone fractures. Study Selection and Data Extraction: Studies were included if they reported results of concomitant use of any listed medications with bisphosphonates and risk of fractures and focused on women. Articles that focused generally on the use of one of the listed medications and fractures without explicitly examining the potential antifracture efficacy or attenuation of bisphosphonates were excluded. Data Synthesis: A total of 6 relevant studies were identified. Four epidemiological studies reported a statistically significant dose-dependent increase in the risk of fractures when bisphosphonates and acid-suppressive drugs were used together. One post hoc analysis of clinical trial data suggested no attenuation of the antifracture effects of bisphosphonates when used concomitantly with acid-suppressive therapy. One study involving bisphosphonates and SSRIs noted a statistically significant association between fracture risk and SSRI use. No study examining TZDs or levothyroxine with bisphosphonates was identified. Conclusions: Existing research suggests potential attenuation of bisphosphonate antifracture efficacy among patients taking acid-suppressive medications. Based on their pharmacological actions, TZDs, SSRIs, and levothyroxine have similar implications. The paucity of evidence in the literature associating the attenuation of bisphosphonate antifracture efficacy when combined with other medications suggests that further investigation is needed.

[1]  Jeannie K. Lee,et al.  Depression, Antidepressants, and Bone Health in Older Adults: A Systematic Review , 2015, Journal of the American Geriatrics Society.

[2]  Osamu Kikuchi,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , 2015 .

[3]  C. Cooper,et al.  Predictors of Fracture While on Treatment With Oral Bisphosphonates: A Population‐Based Cohort Study , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  L. Kux.  OF HEALTH AND HUMAN SERVICES Food and Drug Administration , 2014 .

[5]  N. Watts,et al.  Postmenopausal osteoporosis , 2013, Current Opinion in Endocrinology, Diabetes & Obesity.

[6]  S. Takeda,et al.  The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis , 2013, Journal of Bone and Mineral Metabolism.

[7]  H. Song,et al.  A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate , 2013, Journal of Gastroenterology.

[8]  J. A. Cabrera,et al.  PREVALENCE AND RISK FACTORS FOR NON-VERTEBRAL FRACTURES IN PATIENTS RECEIVING ORAL GLUCOCORTICOIDS , 2012 .

[9]  M. Bush,et al.  Multiple chronic conditions among adults aged 45 and over: trends over the past 10 years. , 2012, NCHS data brief.

[10]  R. Eastell,et al.  Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study , 2012, Osteoporosis International.

[11]  R. Rizzoli,et al.  Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper , 2012, Osteoporosis International.

[12]  R. Eastell,et al.  Proton pump inhibitor use and the antifracture efficacy of alendronate. , 2011, Archives of internal medicine.

[13]  Geoff M. Anderson,et al.  Levothyroxine dose and risk of fractures in older adults: nested case-control study , 2011, BMJ : British Medical Journal.

[14]  Y. Loke,et al.  Meta-analysis: risk of fractures with acid-suppressing medication. , 2011, Bone.

[15]  V. Stearns,et al.  Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management , 2011, Breast Cancer Research.

[16]  M. Schott.  Thyroid Function within the Upper Normal Range Is Associated with Reduced Bone Mineral Density and an Increased Risk of Nonvertebral Fractures in Healthy Euthyroid Postmenopausal Women , 2011 .

[17]  R. Lindsay,et al.  Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors , 2011, Osteoporosis International.

[18]  É. Legrand,et al.  Severity of osteoporosis: what is the impact of co-morbidities? , 2010, Joint, bone, spine : revue du rhumatisme.

[19]  D. Furst,et al.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis , 2010, Arthritis care & research.

[20]  Klaus Klaushofer,et al.  Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  David C. Metz,et al.  Safety of proton pump inhibitor exposure. , 2010, Gastroenterology.

[22]  G. Mazziotti,et al.  Drug-induced osteoporosis: mechanisms and clinical implications. , 2010, The American journal of medicine.

[23]  M. O’Connell,et al.  Drug-induced osteoporosis in the older adult , 2010 .

[24]  A. Giusti,et al.  Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. , 2010, Bone.

[25]  D. Felsenberg,et al.  Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women. , 2010, The Journal of clinical endocrinology and metabolism.

[26]  J. David,et al.  Glucocorticoids suppress bone formation by attenuating osteoblast differentiation via the monomeric glucocorticoid receptor. , 2010, Cell metabolism.

[27]  M. Eijken,et al.  A New Concept Underlying Stem Cell Lineage Skewing That Explains the Detrimental Effects of Thiazolidinediones on Bone , 2010, Stem cells.

[28]  C. Colón-Emeric,et al.  A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. , 2010, The American journal of geriatric pharmacotherapy.

[29]  A. LaCroix,et al.  Antiepileptic Drug Use, Falls, Fractures, and BMD in Postmenopausal Women: Findings From the Women's Health Initiative (WHI) , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  C. Roux.  Potential effects of bisphosphonates on bone ultrastructure , 2009, Osteoporosis International.

[31]  C. Cooper,et al.  Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates , 2009, Osteoporosis International.

[32]  Sidney H Kennedy,et al.  Real-World Data on SSRI Antidepressant Side Effects. , 2009, Psychiatry (Edgmont (Pa. : Township)).

[33]  P. Dayer,et al.  Low-Energy Femoral Fractures Associated with the Long-Term Use of Bisphosphonates , 2009, Drug safety.

[34]  R. Aparasu,et al.  Clinically important potential drug-drug interactions in outpatient settings. , 2007, Research in social & administrative pharmacy : RSAP.

[35]  R. Russell,et al.  Bisphosphonates: Mode of Action and Pharmacology , 2007, Pediatrics.

[36]  C. Cooper,et al.  Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population‐based case–control study , 2007, Journal of internal medicine.

[37]  R. Civitelli,et al.  Safety Considerations with Bisphosphonates for the Treatment of Osteoporosis , 2007, Drug safety.

[38]  J. Avrunin,et al.  Fracture risk and antiresorptive medication use in older women in the USA , 2007, Osteoporosis International.

[39]  C. Chenu,et al.  Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. , 2006, Bone.

[40]  G. Karsenty,et al.  Convergence between bone and energy homeostases: leptin regulation of bone mass. , 2006, Cell metabolism.

[41]  P. Vestergaard,et al.  Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture , 2006, Calcified Tissue International.

[42]  N. Franceschini,et al.  Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures , 2006, Clinical Rheumatology.

[43]  Connie M Weaver,et al.  The role of calcium in peri- and postmenopausal women: 2006 position statement of the North American Menopause Society. , 2006, Menopause.

[44]  P. Vestergaard,et al.  Fracture risk associated with systemic and topical corticosteroids , 2005, Journal of internal medicine.

[45]  Joyce H. Keyak,et al.  Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naïve postmenopausal women , 2005, Osteoporosis International.

[46]  J. Freston.  Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. , 2004, The American journal of medicine.

[47]  R. Victor,et al.  Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. , 2004, The American journal of medicine.

[48]  P. Vestergaard,et al.  Corticosteroid use and risk of hip fracture: a population‐based case–control study in Denmark , 2003, Journal of internal medicine.

[49]  R. Cumming,et al.  Benzodiazepines and Risk of Hip Fractures in Older People , 2003, CNS drugs.

[50]  Patricia Ducy,et al.  Leptin Regulates Bone Formation via the Sympathetic Nervous System , 2002, Cell.

[51]  A. Gibofsky.  American College of Rheumatology. , 2002, Journal of the Medical Association of Georgia.

[52]  M. Bliziotes,et al.  Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. , 2001, Bone.

[53]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[54]  Dami,et al.  EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN EFFECT OF RISEDRONATE ON THE RISK OF HIP FRACTURE IN ELDERLY WOMEN , 2001 .

[55]  A. McMahon,et al.  Design issues for drug epidemiology. , 2000, British journal of clinical pharmacology.

[56]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[57]  H K Genant,et al.  Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. , 1999, JAMA.

[58]  Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. , 1996, Arthritis and rheumatism.